{
  "id": 18082008,
  "title": "China biotech Minghui does thyroid eye disease deal for $110M upfront",
  "url": "https://urgent.news/2026/11/04/china-biotech-minghui-does-thyroid-eye-disease-deal-for-110m-upfront",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-04T07:04:40.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/china-biotech-minghui-does-thyroid-eye-disease-deal-for-110m-upfront/"
  },
  "original_language": "en",
  "account": null,
  "summary": "A Chinese biotech is selling the Japanese rights for its Phase 3 thyroid eye disease drug to a 106-year-old specialty pharma long known for its thyroid hormone business. Shanghai-based Minghui Pharmaceutical will ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}